Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy.

Doornhof, K R; van der Linden, P D; Boeke, G M; Willemsen, A E C A B; Daskapan, A

Doornhof, K R; van der Linden, P D; Boeke, G M; Willemsen, A E C A B; Daskapan, A.

Afiliación

Doornhof KR; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
van der Linden PD; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
Boeke GM; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands.
Willemsen AECAB; Department of Internal Medicine, Tergooi Medical Center, Hilversum, The Netherlands.
Daskapan A; Department of Clinical Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands. a.daskapan@gmail.com.

Eur J Clin Pharmacol ; 79(4): 493-501, 2023 Apr.

Article en En | MEDLINE | ID: mdl-36757428

Asunto(s)

Antimetabolitos Antineoplásicos; Dihidrouracilo Deshidrogenasa (NADP); Humanos; Dihidrouracilo Deshidrogenasa (NADP)/genética; Estudios Retrospectivos; Leucocitos Mononucleares; Estudios Prospectivos; Fenotipo; Fluorouracilo/uso terapéutico

Palabras clave

5FU; Adverse events; Capecitabine; Chemotherapy; DPD; Fluoropyrimidine therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dihidrouracilo Deshidrogenasa (NADP) / Antimetabolitos Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google